Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ASENSUS SURGICAL, INC.TRXC · Entity 88098 | Director | April 25, 2019 | April 26, 2019 |
| Merck & Co., Inc.MRK · Entity 2807 | Director | March 30, 2012 | April 03, 2012 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ASENSUS SURGICAL, INC.
Report date April 25, 2019 · Filed April 26, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 90,742 |
Reported balance
After 2019-04-25 transaction · row 1
1 source rowRow 1 · 2019-04-25 · Grant · Acquired 20,380 · Balance 90,742 F1: Represents restricted stock units. Each restricted stock unit represents the right to receive one share of the Registrant's common stock. F2: The restricted stock units remain subject to forfeiture until the first anniversary of the date of grant or, if earlier, the date of the next annual meeting of stockholders, as long as the reporting person remains in continuous service during the vesting period. |
| Stock Option AwardSEC Table II · derivative / convertible security · Conversion / exercise price $1.96 · Expires 2029-04-25 | Direct | 29,104 |
Reported balance
After 2019-04-25 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2019-04-25 · Grant · Acquired 29,104 · Balance 29,104 F3: The vesting schedule is 25% of the stock option award on July 1, 2019, October 1, 2019, January 1, 2020 and April 1, 2020. Subject to acceleration of vesting in full upon consummation of a change in control of the registrant. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted stock units. Each restricted stock unit represents the right to receive one share of the Registrant's common stock.
F2: The restricted stock units remain subject to forfeiture until the first anniversary of the date of grant or, if earlier, the date of the next annual meeting of stockholders, as long as the reporting person remains in continuous service during the vesting period.
F3: The vesting schedule is 25% of the stock option award on July 1, 2019, October 1, 2019, January 1, 2020 and April 1, 2020. Subject to acceleration of vesting in full upon consummation of a change in control of the registrant.
Merck & Co., Inc.
Report date March 30, 2012 · Filed April 03, 2012
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Phantom StockSEC Table II · derivative / convertible security | Direct | 72,230.1349 |
Reported balance
After 2012-03-30 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2012-03-30 · Grant · Acquired 748.6979 · Balance 72,230.1349 F1: 1-for-1 F2: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F3: Holdings include shares acquired in dividend reinvestment transactions. |
| Common StockSEC Table I · non-derivative | Direct | 3,561 |
Reported balance
Holding disclosure · report date 2012-03-30 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 3,561 |
| Common StockSEC Table I · non-derivative | IndirectBy IRA | 750 |
Reported balance
Holding disclosure · report date 2012-03-30 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 750 |
Filing footnotes · ownership attribution and instrument terms
F1: 1-for-1
F2: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation.
F3: Holdings include shares acquired in dividend reinvestment transactions.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
GENVEC INC
Report date June 16, 2017 · Filed June 20, 2017
Section 16 reporting ended · disclosed 2017-06-20. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2017-06-16 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2017-06-16 · Exercise / conversion · Acquired 1,500 · Balance 9,050 Row 2 · 2017-06-16 · Tax withholding · Disposed 793 · Balance 8,257 F1: Withholding of Common Stock to pay exercise price. Row 3 · 2017-06-16 · Disposition to issuer · Disposed 8,257 · Balance 0 F2: The shares of Common Stock were cancelled pursuant to the Agreement and Plan of Merger, dated January 24, 2017, among the Issuer, Intrexon Corporation ("Intrexon") and Intrexon GV Holding, Inc. (the "Merger Agreement") in exchange for (i) 2,452 shares of Intrexon common stock having a market value of $55,955 as of the close of trading on the date immediately prior to the effective date of the merger, and cash in lieu of fractional shares of Intrexon common stock, plus (ii) one contingent payment right (the "Merger Consideration"). F3: [footnote 2 continued] Each contingent payment right entitles the holder thereof to an amount equal to half of certain payments actually received by the registrant or its successor or any of their affiliates from or on behalf of Novartis Institutes for BioMedical Research, Inc. ("Novartis") under the Research Collaboration and License Agreement, dated January 13, 2010, as amended, between the registrant and Novartis, on account of milestone payments or royalties due in relation to the period ending June 16, 2019, divided by the number of shares of the regisrant's common stock having rights to the Merger Consideration, subject to any withholding of taxes required by applicable law. F4: Disposed of pursuant to the Merger Agreement in exchange for the Merger Consideration. |
| Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.80 · Expires 2017-06-16 | Direct | 0 |
Reported balance
After 2017-06-16 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2017-06-16 · Exercise / conversion · Disposed 1,500 · Balance 0 F5: Pursuant to the Merger Agreement, the vesting date of unvested stock options accelerated to vest and become exercisable as of the closing of the merger. |
Filing footnotes · ownership attribution and instrument terms
F1: Withholding of Common Stock to pay exercise price.
F2: The shares of Common Stock were cancelled pursuant to the Agreement and Plan of Merger, dated January 24, 2017, among the Issuer, Intrexon Corporation ("Intrexon") and Intrexon GV Holding, Inc. (the "Merger Agreement") in exchange for (i) 2,452 shares of Intrexon common stock having a market value of $55,955 as of the close of trading on the date immediately prior to the effective date of the merger, and cash in lieu of fractional shares of Intrexon common stock, plus (ii) one contingent payment right (the "Merger Consideration").
F3: [footnote 2 continued] Each contingent payment right entitles the holder thereof to an amount equal to half of certain payments actually received by the registrant or its successor or any of their affiliates from or on behalf of Novartis Institutes for BioMedical Research, Inc. ("Novartis") under the Research Collaboration and License Agreement, dated January 13, 2010, as amended, between the registrant and Novartis, on account of milestone payments or royalties due in relation to the period ending June 16, 2019, divided by the number of shares of the regisrant's common stock having rights to the Merger Consideration, subject to any withholding of taxes required by applicable law.
F4: Disposed of pursuant to the Merger Agreement in exchange for the Merger Consideration.
F5: Pursuant to the Merger Agreement, the vesting date of unvested stock options accelerated to vest and become exercisable as of the closing of the merger.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 25, 2019 Filed Apr 26, 2019 20:02 UTC | ASENSUS SURGICAL, INC. TRXC · Entity 88098 | GrantStock Option Award · Derivative | 29,104 | $0.00 Strike: $1.96 | $0.00 |
DisclosureSEC source: 0001209191-19-026317 · doc4.xml · derivative · entry 2 KELLEY WILLAM N · CIK 0001204361 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,104 Underlying: Common Stock · 29,104 shares Expires 2029-04-25 F3 · derivative.exercise_date: The vesting schedule is 25% of the stock option award on July 1, 2019, October 1, 2019, January 1, 2020 and April 1, 2020. Subject to acceleration of vesting in full upon consummation of a change in control of the registrant. Read SEC document |
| April 25, 2019 Filed Apr 26, 2019 20:02 UTC | ASENSUS SURGICAL, INC. TRXC · Entity 88098 | GrantCommon Stock | 20,380 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-026317 · doc4.xml · nonDerivative · entry 1 KELLEY WILLAM N · CIK 0001204361 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,742 F1 · shares: Represents restricted stock units. Each restricted stock unit represents the right to receive one share of the Registrant's common stock. F2 · shares: The restricted stock units remain subject to forfeiture until the first anniversary of the date of grant or, if earlier, the date of the next annual meeting of stockholders, as long as the reporting person remains in continuous service during the vesting period. F1 · price: Represents restricted stock units. Each restricted stock unit represents the right to receive one share of the Registrant's common stock. Read SEC document |
| May 24, 2018 Filed May 29, 2018 07:02 UTC | ASENSUS SURGICAL, INC. TRXC · Entity 88098 | GrantStock Option Award · Derivative | 35,592 | $0.00 Strike: $3.17 | $0.00 |
DisclosureSEC source: 0001209191-18-033658 · doc4.xml · derivative · entry 2 KELLEY WILLAM N · CIK 0001204361 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,592 Underlying: Common Stock · 35,592 shares Expires 2028-05-24 F3 · derivative.exercise_date: The vesting schedule is 25% of the stock option award on each of July 1, 2018, October 1, 2018, January 1, 2019 and April 1, 2019. Read SEC document |
| May 24, 2018 Filed May 29, 2018 07:02 UTC | ASENSUS SURGICAL, INC. TRXC · Entity 88098 | GrantCommon Stock | 20,362 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-18-033658 · doc4.xml · nonDerivative · entry 1 KELLEY WILLAM N · CIK 0001204361 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,362 F1 · security: Represents restricted stock units. Each restricted stock unit represents the right to receive one share of the Registrant's common stock. F1 · price: Represents restricted stock units. Each restricted stock unit represents the right to receive one share of the Registrant's common stock. F2 · price: The restricted stock units remain subject to forfeiture until the first anniversary of the date of grant or, if earlier, the date of the next annual meeting of stockholders, as long as the reporting person remains in continuous service during the vesting period. Read SEC document |
| August 08, 2017 Filed Aug 9, 2017 06:37 UTC | ASENSUS SURGICAL, INC. TRXC · Entity 88098 | PurchaseCommon Stock | 30,000 | $0.71 | $21,174.00 |
DisclosureSEC source: 0001209191-17-048200 · doc4.xml · nonDerivative · entry 1 KELLEY WILLAM N · CIK 0001204361 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 F1 · ownership.direct: 20,000 shares are held jointly by the Reporting Person and his spouse. Read SEC document |
| June 16, 2017 Filed Jun 20, 2017 16:35 UTC | GENVEC INC GNVC · Entity 175088 | Exercise / conversionStock Options (right to buy) · Derivative | 1,500 | $3.80 Strike: $3.80 | $5,700.00 |
DisclosureSEC source: 0001123292-17-001165 · edgar.xml · derivative · entry 4 KELLEY WILLAM N · CIK 0001204361 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,500 shares Expires 2017-06-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Pursuant to the Merger Agreement, the vesting date of unvested stock options accelerated to vest and become exercisable as of the closing of the merger. Read SEC document |
| June 16, 2017 Filed Jun 20, 2017 16:35 UTC | GENVEC INC GNVC · Entity 175088 | Disposition to issuerCommon Stock | 8,257 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001123292-17-001165 · edgar.xml · nonDerivative · entry 3 KELLEY WILLAM N · CIK 0001204361 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F2 · shares: The shares of Common Stock were cancelled pursuant to the Agreement and Plan of Merger, dated January 24, 2017, among the Issuer, Intrexon Corporation ("Intrexon") and Intrexon GV Holding, Inc. (the "Merger Agreement") in exchange for (i) 2,452 shares of Intrexon common stock having a market value of $55,955 as of the close of trading on the date immediately prior to the effective date of the merger, and cash in lieu of fractional shares of Intrexon common stock, plus (ii) one contingent payment right (the "Merger Consideration"). F3 · shares: [footnote 2 continued] Each contingent payment right entitles the holder thereof to an amount equal to half of certain payments actually received by the registrant or its successor or any of their affiliates from or on behalf of Novartis Institutes for BioMedical Research, Inc. ("Novartis") under the Research Collaboration and License Agreement, dated January 13, 2010, as amended, between the registrant and Novartis, on account of milestone payments or royalties due in relation to the period ending June 16, 2019, divided by the number of shares of the regisrant's common stock having rights to the Merger Consideration, subject to any withholding of taxes required by applicable law. F4 · price: Disposed of pursuant to the Merger Agreement in exchange for the Merger Consideration. Read SEC document |
| June 16, 2017 Filed Jun 20, 2017 16:35 UTC | GENVEC INC GNVC · Entity 175088 | Tax withholdingCommon Stock | 793 | $7.19 | $5,701.67 |
DisclosureSEC source: 0001123292-17-001165 · edgar.xml · nonDerivative · entry 2 KELLEY WILLAM N · CIK 0001204361 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,257 F1 · kind: Withholding of Common Stock to pay exercise price. Read SEC document |
| June 16, 2017 Filed Jun 20, 2017 16:35 UTC | GENVEC INC GNVC · Entity 175088 | Exercise / conversionCommon Stock | 1,500 | $3.80 | $5,700.00 |
DisclosureSEC source: 0001123292-17-001165 · edgar.xml · nonDerivative · entry 1 KELLEY WILLAM N · CIK 0001204361 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,050 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 25, 2017 Filed May 26, 2017 16:18 UTC | ASENSUS SURGICAL, INC. TRXC · Entity 88098 | GrantStock Option Award · Derivative | 25,000 | $0.00 Strike: $0.48 | $0.00 |
DisclosureSEC source: 0001209191-17-035809 · doc4.xml · derivative · entry 1 KELLEY WILLAM N · CIK 0001204361 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2027-05-25 F1 · derivative.exercise_date: Vests 25% per quarter on each quarterly anniversary of the date of grant with the final vesting on the first anniversary of the date of grant. Read SEC document |
| October 20, 2016 Filed Oct 24, 2016 16:46 UTC | GENVEC INC GNVC · Entity 175088 | GrantStock Options (right to buy) · Derivative | 15,000 | $0.00 Strike: $0.38 | $0.00 |
DisclosureSEC source: 0001140361-16-083403 · doc1.xml · derivative · entry 1 KELLEY WILLAM N · CIK 0001204361 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2026-10-20 Read SEC document |
| March 30, 2012 Filed Apr 3, 2012 15:58 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantPhantom Stock · Derivative | 748.6979 | $38.40 | $28,750.00 |
DisclosureSEC source: 0001225208-12-008833 · doc4.xml · derivative · entry 3 KELLEY WILLAM N · CIK 0001204361 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,230.1349 Underlying: Common Stock · 748.6979 shares Expires not disclosed F1 · derivative.exercise_price: 1-for-1 F2 · derivative.exercise_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F2 · derivative.expiration_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F3 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| December 30, 2011 Filed Jan 4, 2012 20:02 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantPhantom Stock · Derivative | 762.5995 | $37.70 | $28,750.00 |
DisclosureSEC source: 0001225208-12-000392 · doc4.xml · derivative · entry 3 KELLEY WILLAM N · CIK 0001204361 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,716.1215 Underlying: Common Stock · 762.5995 shares Expires not disclosed F1 · derivative.exercise_price: 1-for-1 F2 · derivative.exercise_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F2 · derivative.expiration_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F3 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| September 30, 2011 Filed Oct 4, 2011 17:34 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantPhantom Stock · Derivative | 879.2049 | $32.70 | $28,750.00 |
DisclosureSEC source: 0001225208-11-022663 · doc4.xml · derivative · entry 3 KELLEY WILLAM N · CIK 0001204361 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,133.0079 Underlying: Common Stock · 879.2049 shares Expires not disclosed F1 · derivative.exercise_price: 1-for-1 F2 · derivative.exercise_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F2 · derivative.expiration_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F3 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| June 30, 2011 Filed Jul 1, 2011 13:47 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantPhantom Stock · Derivative | 814.6784 | $35.29 | $28,750.00 |
DisclosureSEC source: 0001225208-11-016982 · doc4.xml · derivative · entry 3 KELLEY WILLAM N · CIK 0001204361 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,551.6977 Underlying: Common Stock · 814.6784 shares Expires not disclosed F1 · derivative.exercise_price: 1-for-1 F2 · derivative.exercise_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F2 · derivative.expiration_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F3 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| May 27, 2011 Filed May 31, 2011 14:44 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantPhantom Stock · Derivative | 4,142.5021 | $36.21 | $150,000.00 |
DisclosureSEC source: 0001225208-11-015338 · doc4.xml · derivative · entry 3 KELLEY WILLAM N · CIK 0001204361 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,737.0193 Underlying: Common Stock · 4,142.5021 shares Expires not disclosed F1 · derivative.exercise_price: 1-for-1 F2 · derivative.exercise_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F2 · derivative.expiration_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F3 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| March 31, 2011 Filed Apr 1, 2011 12:59 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantPhantom Stock · Derivative | 870.9482 | $33.01 | $28,750.00 |
DisclosureSEC source: 0001225208-11-010581 · doc4.xml · derivative · entry 3 KELLEY WILLAM N · CIK 0001204361 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,898.7312 Underlying: Common Stock · 870.9482 shares Expires not disclosed F1 · derivative.exercise_price: 1-for-1 F2 · derivative.exercise_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F2 · derivative.expiration_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F3 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| December 31, 2010 Filed Jan 3, 2011 17:51 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantPhantom Stock · Derivative | 658.99 | $36.04 | $23,750.00 |
DisclosureSEC source: 0001225208-11-000083 · doc4.xml · derivative · entry 3 KELLEY WILLAM N · CIK 0001204361 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,419.7749 Underlying: Common Stock · 658.99 shares Expires not disclosed F1 · derivative.exercise_price: 1-for-1 F2 · derivative.exercise_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F2 · derivative.expiration_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F3 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| September 30, 2010 Filed Oct 1, 2010 21:06 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantPhantom Stock · Derivative | 808.2043 | $36.81 | $29,750.00 |
DisclosureSEC source: 0001225208-10-021736 · doc4.xml · derivative · entry 3 KELLEY WILLAM N · CIK 0001204361 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,156.7949 Underlying: Common Stock · 808.2043 shares Expires not disclosed F1 · derivative.exercise_price: 1-for-1 F2 · derivative.exercise_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F2 · derivative.expiration_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F3 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| August 04, 2010 Filed Aug 6, 2010 14:53 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantStock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $35.19 | $0.00 |
DisclosureSEC source: 0001225208-10-018702 · doc4.xml · derivative · entry 3 KELLEY WILLAM N · CIK 0001204361 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2020-08-03 F1 · derivative.exercise_date: The option vests in three equal annual installments beginning August 4, 2011. Read SEC document |
| June 30, 2010 Filed Jul 1, 2010 18:14 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantPhantom Stock · Derivative | 636.2597 | $34.97 | $22,250.00 |
DisclosureSEC source: 0001225208-10-015976 · doc4.xml · derivative · entry 3 KELLEY WILLAM N · CIK 0001204361 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,743.4396 Underlying: Common Stock · 636.2597 shares Expires not disclosed F1 · derivative.exercise_price: 1-for-1 F2 · derivative.exercise_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F2 · derivative.expiration_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F3 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| May 28, 2010 Filed Jun 1, 2010 19:58 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantPhantom Stock · Derivative | 1,632.5319 | $33.69 | $55,000.00 |
DisclosureSEC source: 0001225208-10-014284 · doc4.xml · derivative · entry 3 KELLEY WILLAM N · CIK 0001204361 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,107.1799 Underlying: Common Stock · 1,632.5319 shares Expires not disclosed F1 · derivative.exercise_price: 1-for-1 F2 · derivative.exercise_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F2 · derivative.expiration_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F3 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| March 31, 2010 Filed Apr 2, 2010 16:14 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantPhantom Stock · Derivative | 876.8407 | $37.35 | $32,750.00 |
DisclosureSEC source: 0001225208-10-009542 · doc4.xml · derivative · entry 3 KELLEY WILLAM N · CIK 0001204361 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,916.4782 Underlying: Common Stock · 876.8407 shares Expires not disclosed F1 · derivative.exercise_price: 1-for-1 F2 · derivative.exercise_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F2 · derivative.expiration_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F3 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| December 31, 2009 Filed Jan 4, 2010 19:43 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantPhantom Stock · Derivative | 855.2271 | $36.54 Strike: $0.00 | $31,250.00 |
DisclosureSEC source: 0001225208-10-000142 · doc4.xml · derivative · entry 3 KELLEY WILLAM N · CIK 0001204361 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,508.9105 Underlying: Common Stock · 855.2271 shares Expires not disclosed F1 · derivative.exercise_price: 1-for-1 F2 · derivative.exercise_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F2 · derivative.expiration_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F3 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| November 03, 2009 Filed Nov 6, 2009 02:35 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantStock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $24.30 | $0.00 |
DisclosureSEC source: 0001225208-09-021804 · doc4.xml · derivative · entry 13 KELLEY WILLAM N · CIK 0001204361 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2019-04-30 F3 · price: This option, which vests in three equal annual installments beginning one year from date of grant, was assumed in the Transaction and continued on the same terms and conditions for an option to purchase an equivalent number of shares of MSD common stock at the same exercise price as applied prior to the merger. Read SEC document |
| November 03, 2009 Filed Nov 6, 2009 02:35 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantStock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $38.04 | $0.00 |
DisclosureSEC source: 0001225208-09-021804 · doc4.xml · derivative · entry 12 KELLEY WILLAM N · CIK 0001204361 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2018-04-29 F3 · price: This option, which vests in three equal annual installments beginning one year from date of grant, was assumed in the Transaction and continued on the same terms and conditions for an option to purchase an equivalent number of shares of MSD common stock at the same exercise price as applied prior to the merger. Read SEC document |
| November 03, 2009 Filed Nov 6, 2009 02:35 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantStock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $51.86 | $0.00 |
DisclosureSEC source: 0001225208-09-021804 · doc4.xml · derivative · entry 11 KELLEY WILLAM N · CIK 0001204361 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2017-04-26 F3 · price: This option, which vests in three equal annual installments beginning one year from date of grant, was assumed in the Transaction and continued on the same terms and conditions for an option to purchase an equivalent number of shares of MSD common stock at the same exercise price as applied prior to the merger. Read SEC document |
| November 03, 2009 Filed Nov 6, 2009 02:35 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantStock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $34.44 | $0.00 |
DisclosureSEC source: 0001225208-09-021804 · doc4.xml · derivative · entry 10 KELLEY WILLAM N · CIK 0001204361 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2016-04-27 F3 · price: This option, which vests in three equal annual installments beginning one year from date of grant, was assumed in the Transaction and continued on the same terms and conditions for an option to purchase an equivalent number of shares of MSD common stock at the same exercise price as applied prior to the merger. Read SEC document |
| November 03, 2009 Filed Nov 6, 2009 02:35 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantStock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $33.83 | $0.00 |
DisclosureSEC source: 0001225208-09-021804 · doc4.xml · derivative · entry 9 KELLEY WILLAM N · CIK 0001204361 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2015-04-28 F3 · price: This option, which vests in three equal annual installments beginning one year from date of grant, was assumed in the Transaction and continued on the same terms and conditions for an option to purchase an equivalent number of shares of MSD common stock at the same exercise price as applied prior to the merger. Read SEC document |
| November 03, 2009 Filed Nov 6, 2009 02:35 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantStock Option (right to buy) · Derivative | 5,275 | $0.00 Strike: $71.30 | $0.00 |
DisclosureSEC source: 0001225208-09-021804 · doc4.xml · derivative · entry 8 KELLEY WILLAM N · CIK 0001204361 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,275 Underlying: Common Stock · 5,275 shares Expires 2011-04-26 F4 · price: This option, which vesting on the exercisable date, was assumed in the Transaction and continued on the same terms and conditions for an option to purchase an equivalent number of shares of MSD common stock at the same exercise price as applied prior to the merger. Read SEC document |
| November 03, 2009 Filed Nov 6, 2009 02:35 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantStock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $47.23 | $0.00 |
DisclosureSEC source: 0001225208-09-021804 · doc4.xml · derivative · entry 7 KELLEY WILLAM N · CIK 0001204361 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2014-04-29 F3 · price: This option, which vests in three equal annual installments beginning one year from date of grant, was assumed in the Transaction and continued on the same terms and conditions for an option to purchase an equivalent number of shares of MSD common stock at the same exercise price as applied prior to the merger. Read SEC document |
| November 03, 2009 Filed Nov 6, 2009 02:35 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantStock Option (right to buy) · Derivative | 5,275 | $0.00 Strike: $65.88 | $0.00 |
DisclosureSEC source: 0001225208-09-021804 · doc4.xml · derivative · entry 6 KELLEY WILLAM N · CIK 0001204361 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,275 Underlying: Common Stock · 5,275 shares Expires 2010-04-27 F4 · price: This option, which vesting on the exercisable date, was assumed in the Transaction and continued on the same terms and conditions for an option to purchase an equivalent number of shares of MSD common stock at the same exercise price as applied prior to the merger. Read SEC document |
| November 03, 2009 Filed Nov 6, 2009 02:35 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantStock Option (right to buy) · Derivative | 5,275 | $0.00 Strike: $53.84 | $0.00 |
DisclosureSEC source: 0001225208-09-021804 · doc4.xml · derivative · entry 5 KELLEY WILLAM N · CIK 0001204361 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,275 Underlying: Common Stock · 5,275 shares Expires 2013-04-27 F3 · price: This option, which vests in three equal annual installments beginning one year from date of grant, was assumed in the Transaction and continued on the same terms and conditions for an option to purchase an equivalent number of shares of MSD common stock at the same exercise price as applied prior to the merger. Read SEC document |
| November 03, 2009 Filed Nov 6, 2009 02:35 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantStock Option (right to buy) · Derivative | 5,275 | $0.00 Strike: $51.60 | $0.00 |
DisclosureSEC source: 0001225208-09-021804 · doc4.xml · derivative · entry 4 KELLEY WILLAM N · CIK 0001204361 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,275 Underlying: Common Stock · 5,275 shares Expires 2012-04-25 F3 · price: This option, which vests in three equal annual installments beginning one year from date of grant, was assumed in the Transaction and continued on the same terms and conditions for an option to purchase an equivalent number of shares of MSD common stock at the same exercise price as applied prior to the merger. Read SEC document |
| November 03, 2009 Filed Nov 6, 2009 02:35 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantPhantom Stock · Derivative | 52,653.6834 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001225208-09-021804 · doc4.xml · derivative · entry 3 KELLEY WILLAM N · CIK 0001204361 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,653.6834 Underlying: Common Stock · 52,653.6834 shares Expires not disclosed F2 · derivative.exercise_price: Each share of phantom stock is the economic equivalent of one share of Merck & Co., Inc. Common Stock, pursuant to the Plan for Deferred Payment of Directors Compensation, and was exchanged for an equal number of shares of phantom stock of MSD in connection with the Transactions. F2 · derivative.exercise_date: Each share of phantom stock is the economic equivalent of one share of Merck & Co., Inc. Common Stock, pursuant to the Plan for Deferred Payment of Directors Compensation, and was exchanged for an equal number of shares of phantom stock of MSD in connection with the Transactions. F2 · derivative.expiration_date: Each share of phantom stock is the economic equivalent of one share of Merck & Co., Inc. Common Stock, pursuant to the Plan for Deferred Payment of Directors Compensation, and was exchanged for an equal number of shares of phantom stock of MSD in connection with the Transactions. Read SEC document |
| November 03, 2009 Filed Nov 6, 2009 02:35 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantCommon Stock | 750 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-09-021804 · doc4.xml · nonDerivative · entry 2 KELLEY WILLAM N · CIK 0001204361 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By IRA Disclosed balance after: 750 F1 · price: Received in exchange for an equivalent number of shares of Merck Sharp & Dohme Corp. (formerly Merck & Co., Inc.) ("MSD") common stock in connection with the completion of transactions contemplated by the Agreement and Plan of Merger by and among, inter alia, MSD and Merck & Co., Inc. (formerly Schering-Plough Corporation) (the "Transactions"). Read SEC document |
| November 03, 2009 Filed Nov 6, 2009 02:35 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantCommon Stock | 3,561 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-09-021804 · doc4.xml · nonDerivative · entry 1 KELLEY WILLAM N · CIK 0001204361 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,561 F1 · price: Received in exchange for an equivalent number of shares of Merck Sharp & Dohme Corp. (formerly Merck & Co., Inc.) ("MSD") common stock in connection with the completion of transactions contemplated by the Agreement and Plan of Merger by and among, inter alia, MSD and Merck & Co., Inc. (formerly Schering-Plough Corporation) (the "Transactions"). Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.